Ignite Creation Date:
2024-05-06 @ 9:02 AM
Last Modification Date:
2024-10-26 @ 12:08 PM
Study NCT ID:
NCT02881697
Status:
COMPLETED
Last Update Posted:
2019-08-14
First Post:
2016-08-18
Brief Title:
mTOR and Adipose Tissue Inflammation
Sponsor:
University Hospital Basel Switzerland
Organization:
University Hospital Basel Switzerland
Study Overview
Official Title:
mTOR and Adipose Tissue Inflammation in Humans
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The target of rapamycin complex 2 TORC2 is an evolutionarily conserved serinethreonine protein kinase that controls growth and metabolism In mammals including humans mammalian TOR complex 2mTORC2 contains mammalian TOR mTOR RICTOR mSIN1 protein and mLST8 gene In an animal model the adipose-specific rictor knockout AdRiKO mouse systemic insulin resistance hepatic steatosis and cardiovascular dysfunction develop upon high fat diet HFD-induced obesity or aging To find a molecular link between adipose mTORC2 and systemic insulin resistance investigators have already performed transcriptomics and proteomics analysis on visceral white adipose tissue in a mouse model The aim of the study is to confirm a molecular link between adipose mTORC2 and systemic insulin resistance in humans
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None